11月24日，华恒生物涨5.3%，截至发稿，报33.98元/股，成交2.13亿元，换手率2.55%，总市值84.99亿 元。 资料显示，安徽华恒生物科技股份有限公司位于安徽省合肥市高新区长安路197号,香港铜锣湾希慎道33 号利园1期19楼1901室，成立日期2005年4月13日，上市日期2021年4月22日，公司主营业务涉及氨基酸 及其衍生物产品研发、生产、销售。主营业务收入构成为：氨基酸系列70.96%，其他(补充)20.96%，维 生素系列5.34%，其他产品2.74%。 从华恒生物十大流通股东角度 数据显示，交银施罗德基金旗下1只基金位居华恒生物十大流通股东。交银先进制造混合A（519704） 三季度减持383.68万股，持有股数431.35万股，占流通股的比例为1.72%。根据测算，今日浮盈赚取约 737.61万元。 交银先进制造混合A（519704）成立日期2011年6月22日，最新规模44.97亿。今年以来收益35.48%，同 类排名1407/8209；近一年收益33.53%，同类排名1278/8129；成立以来收益793.9%。 交银先进制造混合A（519704）基金经理为郭若。 截至发稿，郭 ...

Core Viewpoint - Huaheng Biological is a leading biomanufacturing company specializing in amino acids and their derivatives, with a focus on R&D, production, and sales in the food and feed additive sector [1] Group 1: Business Performance - For Q3 2025, Huaheng Biological reported revenue of 2.194 billion yuan, ranking 8th in the industry out of 24 companies, with the industry leader, Meihua Biological, generating 18.215 billion yuan [2] - The net profit for the same period was 159 million yuan, placing the company 9th in the industry, while the top performer, Xinheng, achieved a net profit of 5.354 billion yuan [2] - Year-on-year, the company’s revenue increased by 42.5%, while the net profit saw a slight decline of 1.3% [5] Group 2: Financial Ratios - As of Q3 2025, Huaheng Biological's debt-to-asset ratio stood at 52.96%, higher than the industry average of 28.46%, although it has improved from 60.56% in the previous year [3] - The gross profit margin was reported at 23.55%, below the industry average of 28.77%, and down from 28.13% in the previous year, indicating a need for improvement in profitability [3] Group 3: Leadership and Shareholder Information - The chairman and general manager, Guo Henghua, saw her salary increase from 1.026 million yuan in 2023 to 1.754 million yuan in 2024, an increase of 728,000 yuan [4] - As of September 30, 2025, the number of A-share shareholders increased by 23.84% to 10,200, while the average number of shares held per shareholder decreased by 19.25% to 24,500 [5]

Group 1 - The core viewpoint of the article highlights the recent performance and developments of Huaheng Biological, including stock price changes and significant announcements [1] - On August 11, Huaheng Biological's stock closed at 37.37 yuan, down 0.82% from the previous trading day, with a trading volume of 1.56 billion yuan and a turnover rate of 1.67%, resulting in a total market capitalization of 9.347 billion yuan [1] - The company specializes in the research, production, and sales of amino acids and their derivatives, with applications in food, pharmaceuticals, and feed industries, and is involved in the chemical products sector, including synthetic biology and vitamins [1] Group 2 - On August 11, Huaheng Biological announced that independent director Zhang Qifeng applied for resignation after serving for six consecutive years, and will no longer hold any position in the company, as per relevant regulations requiring the replacement of independent directors upon term expiration [1] - In terms of capital flow, on August 11, there was a net outflow of 10.9682 million yuan from main funds, accounting for 0.12% of the circulating market value, while over the past five days, there was a net inflow of 68.9725 million yuan, representing 0.74% of the circulating market value [1]

Group 1 - As of July 30, 2025, Huaheng Biological's stock price is 33.77 yuan, down 0.74 yuan or 2.14% from the previous trading day [1] - The trading volume on the same day was 54,947 hands, with a transaction amount of 188 million yuan [1] - Huaheng Biological operates in the chemical products industry, focusing on the research, production, and sales of amino acids and their derivatives, which are widely used in food, pharmaceuticals, and feed sectors [1] Group 2 - The company is planning to issue overseas shares and list on the Hong Kong Stock Exchange, with details yet to be determined [1] - This issuance will not change the company's controlling shareholder or actual controller [1] - As of July 30, 2025, the net outflow of main funds for Huaheng Biological was 6.0878 million yuan, accounting for 0.07% of the circulating market value [1]